-
Oct 1, 2007
CAMBRIDGE, Mass., Oct 31, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer...
-
Sep 30, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 30, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today...
-
Sep 3, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 3, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today...
-
Aug 28, 2007
CAMBRIDGE, Mass., Aug 28, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment,...
-
Aug 24, 2007HDAC Inhibitory Activity Disclosed as a Core Component of Multi-Target New Chemical Entity Platform
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 25, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer...
-
Jul 31, 2007
CAMBRIDGE, Mass., Jul 31, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today...
-
Jul 24, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 24, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, will release...
-
Jul 6, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 6, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today...
-
May 18, 2007Ortho Biotech Products, L.P. Terminates License;
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 18, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today...
-
May 11, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 11, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, today...
-
May 10, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 10, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, today...
-
May 9, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, today provided...
-
May 2, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, today reported its...
-
Apr 25, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 25, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, will release its first...
-
Apr 17, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 17, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, today announced that...
-
Apr 11, 2007
CAMBRIDGE, Mass., Apr 11, 2007 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, today announced that...
-
Mar 13, 2007A proprietary small molecule multi-target inhibitor, CUDC-101 is being developed to target EGFR and another clinically validated cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 14, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on novel targeted medicines primarily for cancer treatment, today announced that it...
-
Feb 14, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 14, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focusing on signaling pathway drug technologies to create new medicines primarily for...
-
Feb 1, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2007--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, will...
-
Jan 31, 2007Trial tests safety of systemic administration of a Hedgehog
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 31, 2007--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications,...